ReShape Lifesciences 8-K Enteromedics Announces Preliminary Results from Detailed

©

2009 EnteroMedics

EMPOWER Study

Summary of Ongoing Review

November 2009

Exhibit 99.3

©

2009 EnteroMedics

EMPOWER Efficacy Outcomes

©

2009 EnteroMedics

Optimal Hours of Usage

Mean EWL from Implant (BMI Method) with Standard Error at 12 Months by

Categories of Average Hours of Use per Day through 12 Months

©

2009 EnteroMedics

EWL Through 12 Months

Mean EWL from Implant (BMI Method) by Average Hours of Use per Day with

Standard Error for 12 Month Completer Cohort

-30

-25

-20

-15

-10

-5

0

Study Visit

< 9 hours/day

>= 9 hours/day

N=125

N=128

p<0.0001 at

6 and 12 Months

N=118

N=126

Average Use = 6.9 hrs/day

Average Use = 10.9 hrs/day

©

2009 EnteroMedics

Safety Outcomes: Serious Adverse Events

(SAEs)

No deaths

No Unanticipated Adverse Device Effects (UADEs)

30 SAEs

(see table below)

No therapy-related SAEs

Clinical Events Committee-

Adjudicated Relatedness of SAE

(Event Origin)

VBLOC

Therapy

N=192

Control

N=102

Overall

N=294

Device

3 (1.6%)

1 (1.0%)

4 (1.4%)

General surgical procedure

4 (2.1%)

0 (0.0%)

4 (1.4%)

Implant/revision procedure

3 (1.6%)

2 (2.0%)

5 (1.7%)

Pre-existing condition

9 (4.7%)

8 (7.8%)

17 (5.8%)

Therapy algorithm

0 (0.0%)

0 (0.0%)

0 (0.0%)

©

2009 EnteroMedics

Safety Outcomes: Study Withdrawals

8.5% of patients withdrew in the first 12 Months

©

2009 EnteroMedics

EMPOWER Study

Summary of Ongoing Review

November 2009